Alaunos Therapeutics
TCRT
162 hedge funds and large institutions have $194M invested in Alaunos Therapeutics in 2021 Q3 according to their latest regulatory filings, with 27 funds opening new positions, 62 increasing their positions, 31 reducing their positions, and 19 closing their positions.
855% more call options, than puts
Call options by funds: $16.9M | Put options by funds: $1.77M
100% more repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 31
42% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 19
5% more funds holding
Funds holding: 155 → 162 (+7)
0.02% less ownership
Funds ownership: 0.35% → 0.33% (-0.02%)
35% less capital invested
Capital invested by funds: $297M → $194M (-$103M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$6.12M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.79M |
| 3 |
MWNA
Marshall Wace North America
New York
|
+$1.92M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.66M |
| 5 |
Millennium Management
New York
|
+$1.25M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MVP
Miller Value Partners
Sarasota,
Florida
|
-$27.2M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$6.91M |
| 3 |
JP Morgan Chase
New York
|
-$2.37M |
| 4 |
Charles Schwab
San Francisco,
California
|
-$1.95M |
| 5 |
Citigroup
New York
|
-$872K |
TCRT Hedge Fund Activity: Q3 2021 in Review
162 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q3 2021, worth a combined $194M — down 35% from $297M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new TCRT positions and 19 closed out — a net gain of 8 holders — while 62 added to existing stakes and 31 trimmed.
The largest buyer was Avidity Partners Management, opening a new position worth an estimated $6.12M. The largest seller was Miller Value Partners, exiting entirely with an estimated $27.2M sold.
- 162 institutional investors held Alaunos Therapeutics (TCRT) as of Q3 2021, up from 155 in Q2 2021.
- Funds reported $194M of Alaunos Therapeutics stock for Q3 2021, down 35% quarter-over-quarter.
- 27 funds opened new Alaunos Therapeutics positions in Q3 2021 and 19 closed out, a net change of +8 holders.
- The largest Alaunos Therapeutics buyer in Q3 2021 was Avidity Partners Management, an estimated $6.12M added.
- The largest Alaunos Therapeutics seller in Q3 2021 was Miller Value Partners, an estimated $27.2M sold.
Based on aggregated 13F filings for Q3 2021.